Lenvatinib,sintilimab combined interventional treatment vs bevacizumab,sintilimab combined interventional treatment for intermediate-advanced unresectable hepatocellular carcinoma  

作　　者：Ru-Yu Han Lei-Juan Gan Meng-Ran Lang Shao-Hua Ren Dong-Ming Liu Guang-Tao Li Ya-Yue Liu Xin-Di Tian Kang-Wei Zhu Li-Yu Sun Lu Chen Tian-Qiang Song 

机构地区：[1]Department of Hepatobiliary Cancer,Liver Cancer Center,Tianjin Medical University Cancer Institute&Hospital,National Clinical Research Center for Cancer,Key Laboratory of Cancer Prevention and Therapy,Tianjin’s Clinical Research Center for Cancer,Tianjin Key Laboratory of Digestive Cancer,Tianjin 300060,China [2]Department of Hepatobiliary Surgery,National Cancer Center,National Clinical Research Center for Cancer,Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China

出　　处：《World Journal of Gastroenterology》2024年第43期4620-4635,共16页世界胃肠病学杂志（英文）

基　　金：Supported by The National Natural Science Foundation of China,No.82173317;The Scientific Research Projects of Tianjin Education Commission,No.2022KJ227;The Doctoral Start-up Fund of Tianjin Medical University Cancer Institute&Hospital,No.B2208.

摘　　要：BACKGROUND Bevacizumab and sintilimab combined interventional treatment(BeSiIT)and L envatinib and sintilimab combined interventional treatment(LeSiIT)are two commonly used therapeutic regimens for intermediate-advanced hepatocellular carcinoma(HCC)in clinical practice.AIM To compare the clinical efficacy and safety of BeSiIT and LeSiIT for the treatment of intermediate and advanced HCC.METHODS Patients diagnosed with intermediate-advanced HCC and initially treated with BeSiIT or LeSiIT in the Tianjin Medical University Cancer Institute and Hospital between February 2020 and July 2021 were included.The primary endpoint was progression-free survival(PFS),and the secondary endpoints were overall survival(OS),objective response rate(ORR),disease control rate(DCR),conversion rate,and treatmentrelated adverse events.RESULTS Total 127 patients met the inclusion criteria and were divided into BeSiIT and LeSiIT groups.Twenty-eight and fifty patients in the BeSiIT and LeSiIT groups,respectively,were assessed after 1:2 propensity score matching.PFS and OS rates were not significantly different between the two groups.No significant variations were noted in ORRs or DCRs according to the Response Evaluation Criteria in Solid Tumors(RECIST),and modified RECIST.BeSiIT group showed a better conversion rate than the LeSiIT group(P=0.043).Both groups showed manageable toxicity profiles.Multivariate analysis showed that the independent factors associated with PFS were alphafetoprotein levels and carcinoembryonic antigen score.CONCLUSION In intermediate-to-advanced HCC,the BeSiIT and LeSiIT groups exhibited acceptable toxicities and comparable PFS,OS,and ORR.

关 键 词：Hepatocellular carcinoma Molecular targeted therapy IMMUNOTHERAPY Interventional treatment Propensity score matching 

分 类 号：R735.7[医药卫生—肿瘤]